CN109444415B

CN109444415B - Methoxyproterenol luminescent immunoassay kit

Info

Publication number: CN109444415B
Application number: CN201811548599.7A
Authority: CN
Inventors: 庄路阳; 马雷; 陈小玲; 陈飞; 肖静; 乔晓芳; 李晓霞; 付光宇; 吴学炜
Original assignee: Autobio Diagnostics Co Ltd
Current assignee: Autobio Diagnostics Co Ltd
Priority date: 2018-12-18
Filing date: 2018-12-18
Publication date: 2021-05-28
Anticipated expiration: 2038-12-18
Also published as: CN109444415A

Abstract

The invention discloses a methoxy adrenaline luminescence immunoassay kit, which comprises a detection system and a sample pretreatment system; the detection system comprises a solid phase carrier directly or indirectly coated with an anti-methoxy-adrenaline antibody, a methoxy-adrenaline antibody solution, an avidin-linked tracer solution and a calibrator; the sample pretreatment system comprises an acidification liquid, an acylating agent and an alkaline buffer liquid. The method has the advantages that the defects and the defects of the existing methoxy adrenaline detection method are overcome, the methoxy adrenaline in urine or plasma is firstly subjected to acidification and acylation pretreatment, an acylation agent acylation scheme with biotin at one end is adopted, the acylated methoxy adrenaline is identified and reacted by an antibody, and then the content of the methoxy adrenaline in a sample is accurately determined by combining a method of tracing marker-connected avidin. The prepared kit has high sensitivity and precision. The automation of the detection is realized by utilizing a luminescence technology, and the clinical diagnosis of the pheochromocytoma is assisted.

Description

Methoxyproterenol luminescent immunoassay kit

Technical Field

The invention relates to a biological detection technology, in particular to a methoxy adrenaline luminescence immunoassay kit.

Background

Methaneepinephrine (MN) is a metabolite of epinephrine, and is a useful index for diagnosis of pheochromocytoma, research on causes of hypertension and research on sympathetic nerve functions. MN is a monoamine neurotransmitter, belongs to Catecholamine (CAs), is an endogenous substance with strong physiological activity, and plays an important role in brain and nerve signal transduction. MN is an intermediate metabolite of adrenergic metabolism, is metabolically produced only in adrenal medulla and Pheochromocytoma and Paraganglioma (PPGL) tumors and persists at high concentration levels, and is therefore a specific marker for PPGL.

In adrenal tumor patients, 0.5-1% of the patients are pheochromocytoma, and the pheochromocytoma cells continuously or discontinuously release a large amount of catecholamine substances, so that the symptoms of catecholamine overhigh clinically exist, continuous or paroxysmal hypertension and functional and metabolic disorders of multiple organs are caused, the patients can have symptoms of headache, palpitation, hyperhidrosis triple symptoms, hypertension and the like, and particularly serious patients can have acute left heart failure or cerebrovascular accident. The disease may also develop hypotension, even shock, or appear alternating between hypertension and hypotension. Currently, the detection of catecholamines in plasma is a routine laboratory tool for the diagnosis of pheochromocytoma. Clinically, the relevant examination indexes which are more frequently carried out include adrenaline and noradrenaline, and the metabolite of methoxy noradrenaline and catecholamine, such as vanillylmandelic acid.

At present, the mainstream detection method for the market of the methoxy adrenaline mainly comprises High Performance Liquid Chromatography (HPLC), enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay, but the HPLC is long in time consumption, high in cost and difficult to realize batch detection, and the enzyme-linked immunosorbent assay lacks accuracy and reproducibility.

Disclosure of Invention

The invention aims to provide a methoxy adrenaline luminescence immunoassay kit by using a luminescence method, which is used for detecting the content of methoxy adrenaline in urine so as to provide help for timely diagnosis and treatment of pheochromocytoma.

In order to achieve the purpose, the invention can adopt the following technical scheme:

the methoxy adrenalin luminescence immunoassay kit comprises a detection system and a sample pretreatment system; wherein:

the detection system comprises a solid phase carrier directly or indirectly coated with an anti-methoxy-adrenaline antibody, a methoxy-adrenaline antibody solution, an avidin-linked tracer solution and a calibrator;

the sample pretreatment system comprises an acidification liquid, an acylating agent and an alkaline buffer liquid.

The tracer is at least one of adamantane, acridine ester, luminol and derivatives thereof, isoluminol and derivatives thereof, alkaline phosphatase or horseradish peroxidase.

The avidin is recombinant or natural purified avidin, the using concentration of the avidin is 1/1000-1/20000, and the buffer solution of the avidin comprises 1-50 g/L BSA or other proteins.

The anti-methoxy-epinephrine antibody is an anti-methoxy-epinephrine monoclonal antibody or an anti-methoxy-epinephrine polyclonal antibody; the solid phase carrier can be magnetic microspheres and also can be a transparent or opaque microporous plate.

The diameter of the magnetic microsphere is 0.1-8 μm, and one or more active functional groups including but not limited to-COOH and-NH are connected on the surface₂OH, it can be magnetized quickly under the action of external magnetic field, and after the magnetic field is removed, its residual magnetism is zero.

The anti-methoxy-adrenaline antibody can be coated on the magnetic microsphere through a direct or indirect coating method, and can also be connected on the magnetic microsphere in a reaction mode in the form of an antibody solution.

The indirectly coated magnetic microspheres are indirectly coated by FITC or anti-FITC antibodies or second antibodies.

The calibrator is a series of calibrators with a plurality of different concentration points, wherein the concentration of the methoxy adrenergic antigen ranges from low to high from 0ng/mL to 2000ng/mL, and the buffer solution of the calibrator contains 1-50 g/L of bovine serum albumin and a preservative.

The acylating agent in the sample pretreatment system is an acylating agent with one biotinylated end, and includes but is not limited to 6- (maleimide) hexanoic acid succinimide ester, N- [6- (biotin amino) hexanoyl ] -6-aminocaproic acid N-succinimide ester or N-succinimidyl 6-biotin aminocaproic acid and the like, the using concentration is 0.3-10 mg/mL, and the buffer solution is a phosphoric acid, boric acid and carbonate buffer system.

The pH value of the acidification liquid in the sample pretreatment system is less than 3, such as hydrochloric acid and sulfuric acid; the pH of the alkaline buffer is > 8, and the alkaline buffer comprises NaOH, Tris-NaCl and sodium bicarbonate.

The use method of the kit prepared by the invention comprises the following steps:

1. firstly, preprocessing a sample: adding an acidizing fluid into the urine or plasma sample, acidizing at a high temperature (60-100 ℃ for 15-40 min), cooling to room temperature, adding an acylation reagent, uniformly mixing, reacting for 10-50 min, transferring the treated sample to a reaction cup, and detecting by using an AutoLumo full-automatic detection analyzer.

2. Detection of

2.1 the methoxy adrenaline antibody or FITC-methoxy adrenaline antibody exists in the form of antibody solution, the magnetic particle is connected with a second antibody or FITC antibody which can react with the methoxy adrenaline antibody, and the specific sample adding steps are as follows: a. respectively adding 10-100 mul of the treated calibrator and the sample into different reaction holes; b. adding 10-50 mul of magnetic particle suspension and 10-100 mul of antibody solution; c. incubating at 37 ℃ for 15-30 min, and cleaning for 5 times in a magnetic environment; d. adding 50-200 mul of avidin solution marked with tracer; e. incubating at 37 ℃ for 15-30 min, and cleaning for 5 times in a magnetic environment; f. adding a luminescent substrate, and detecting the intensity of a light signal; g. and calculating the content of the methoxy adrenaline in the sample to be detected according to the detection light intensity of the sample through the reaction curve of the calibrator.

2.2 the methoxy adrenaline is connected to the magnetic particles in a direct or indirect mode, and the specific sample adding steps are as follows: a. respectively adding 10-200 mul of the treated calibrator and the sample into different reaction holes; b. adding 10-50 mul of magnetic particle suspension; c. Incubating at 37 ℃ for 15-30 min, and cleaning for 5 times in a magnetic environment; d. adding 50-200 mul of avidin solution marked with tracer; e. incubating at 37 ℃ for 15-30 min, and cleaning for 5 times in a magnetic environment; f. adding a luminescent substrate, and detecting the intensity of a light signal; g. and calculating the content of the methoxy adrenaline in the sample to be detected according to the detection light intensity of the sample through the reaction curve of the calibrator.

The method adopts a six-point calibration method, firstly takes 6 methoxy adrenaline calibrators with different concentration gradients, measures the luminous values of the calibrators with different concentration gradients in a multi-hole mode, calculates the mean value, respectively takes the concentration value as an X axis and the Log value of the luminous value as a Y axis, and carries out curve fitting according to a (Lin-Log) four-parameter method.

The method for detecting the concentration of the methoxy adrenaline by using the kit comprises the step of adopting a full-automatic chemiluminescence immunoassay analyzer, wherein the used chemiluminescence immunoassay analyzer is preferably an AutoLumo full-automatic detection analyzer (Zhengzhou AnTu bioengineering GmbH).

The method has the advantages that the defects and the defects of the existing methoxy adrenaline detection method are overcome, the methoxy adrenaline in urine or plasma is firstly subjected to acidification and acylation pretreatment, an acylation agent acylation scheme with biotin at one end is adopted, the acylated methoxy adrenaline is identified and reacted by an antibody, and then the content of the methoxy adrenaline in a sample is accurately determined by combining a method of tracing marker-connected avidin. The prepared kit has high sensitivity and precision. The automation of the detection is realized by utilizing a luminescence technology, and the clinical diagnosis of the pheochromocytoma is assisted.

Drawings

FIG. 1 is a graphical representation of the correlation of the kits of the invention with HPLC.

Detailed Description

The present invention is described in more detail below with reference to specific examples to facilitate understanding for those skilled in the art.

The methoxyepinephrine antibody, secondary antibody, avidin labeled tracer (HRP, ALP, luminol and its derivatives, isoluminol and its derivatives, adamantane) used in the examples of the present invention were all from zheng amanuo biotechnology limited.

Reagent components (such as a washing solution and the like which are necessary for some buffers and the like), a kit outer package, independent packaging containers of each reagent component and the like which are not mentioned in detail in the kit of the invention can be carried out according to the conventional operation in the field, and the kit meets the relevant industry regulations. The procedures not mentioned in detail in the method of the kit of the invention can also be carried out with reference to conventional procedures in the art.

EXAMPLE 1 preparation of Methoxyarenol luminescence immunoassay kit

1. Preparation of solid support Material

Preparation of magnetic microsphere suspension: firstly, washing selected magnetic microsphere stock solution for 2-5 times by PBS (phosphate buffer solution) with the volume of 10 times of the stock solution, activating by EDC, NHS or glutaraldehyde, coating the activated magnetic microspheres and antibodies with the concentration of 5-40 mug/mL by any chemical connection method, cleaning the coated magnetic microspheres, sealing by using a sealing solution, fixing the volume, subpackaging, and storing at 2-8 ℃ for later use.

By adopting the method, magnetic particle suspensions of a magnetic particle connected secondary antibody, b magnetic particle connected anti-FITC antibody and c magnetic particle connected anti-methoxy adrenaline antibody can be prepared.

2. Preparation of avidin-linked tracer solutions

Firstly, preparing enzyme solution diluent according to a formula of Tris-NaCL (0.05-0.2M), Bovine Serum Albumin (BSA) (0.5-4%), Aminopyrine (ADP) (0.5-2%), iodopropyne n-butyl carbamate (IPBC-II) (0.5-2%) and polyethylene glycol-4000 (PEG-4000) (0.1-2%), adding avidin to connect with a tracer according to a ratio of 1: 5000-1: 50000 to obtain a solution of avidin-HRP, b, a solution of avidin-ALP, c, a solution of avidin-luminol (derivative), d, a solution of avidin-isoluminol (derivative), e, a solution of avidin-adamantane, f and a solution of avidin-acridine ester, uniformly mixing, and storing at 2-8 ℃ for later use.

3. Preparation of Methoxyproterenol antibody solution

Firstly, preparing an antibody solution diluent according to a formula of Tris-NaCL (0.05-0.2M), Bovine Serum Albumin (BSA) (0.5-4%), Aminopyrine (ADP) (0.5-2%), iodopropyne n-butyl carbamate (IPBC-II) (0.5-2%) and polyethylene glycol-4000 (PEG-4000) (0.1-2%), adding a methoxy adrenaline antibody according to 0.5-10 mu g/mL to prepare an antibody solution, uniformly mixing, and storing at 2-8 ℃ for later use.

4. Preparation of FITC-conjugated Methoxyarenol antibody solution

Adding 2 mg/mL of methoxy-adrenaline antibody into phosphate buffer solution with the pH value of 8.0 by utilizing a Chadwick method, placing the mixture on an ice tank, dissolving FITC by using 3% sodium carbonate aqueous solution, adding 200 mu g/mL of the mixture, mixing the two in equal quantity, continuously stirring the mixture on a magnetic stirrer for 18-24 hours in a refrigerator with the temperature of 0-4 ℃, fully and uniformly mixing the mixture, centrifuging the marked methoxy-adrenaline antibody solution after combination, 2500 r/min for 20 min, removing a small amount of precipitate, placing the mixture into a dialysis bag, placing the dialysis bag into a beaker, and dialyzing the mixture overnight in a refrigerator with buffered saline with the pH value of 8.0 and the temperature of 0-4 ℃.

And adding the purified FITC-methoxy adrenaline antibody into the solution according to the ratio of 0.5-10 mu g/mL to prepare a FITC-methoxy adrenaline antibody solution, uniformly mixing, and storing at 2-8 ℃ for later use.

5. Preparation of sample acidification solution

Measuring a certain volume of acidic solution (such as hydrochloric acid) in a 250 mL beaker, adding 50-250 mL of purified water, and uniformly mixing by shaking until the pH value is less than 3.

6. Preparation of the acylating agent

Weighing a certain volume of N, N-Dimethylformamide (DMF), weighing an appropriate amount of acylating agent, adding the acylating agent into the DMF to completely dissolve the acylating agent, and adding absolute ethyl alcohol (C) in proportion₂H₅OH) and phosphate buffer solution (PBS, the pH value is 5.0-7.4), the concentration of the acylating agent is 1-10 mg/mL, and the mixture is uniformly mixed and stored at the temperature of 2-8 ℃ for later use.

7. Preparation of alkaline solution

Weighing a certain mass of alkaline substance (such as NaOH) into a 250 mL beaker, adding 50-250 mL of purified water, and uniformly mixing by shaking to ensure that the pH value is more than 8.

Example 2 methods of Using the kits of the invention

1. Sample pretreatment: taking 10-50 mu l of urine detection sample, adding 100-300 mu l of acidification solution into a 6 mL glass bottle, carrying out water bath (60-100 ℃) acidification for 0.5-2 h, cooling to room temperature, adding 20-100 mu l of acylating agent, vibrating on an oscillator for 15-30 min, transferring to a reaction cup, and detecting by using an AutoLumo full-automatic detection analyzer.

2. And (3) detection: taking a kit consisting of an avidin-HRP solution, a methoxy adrenergic antibody solution, a general conventional substrate and a cleaning solution as an example: the treated calibrator and the sample were added to the reaction cuvette at a rate of 50. mu.l/well. Mu.l of magnetic particle suspension, 50. mu.l of sample and 50. mu.l of antibody solution are added to each well, mixed uniformly, incubated at 37 ℃ for 15 min, and washed 6 times with washing solution. And adding 100 mu l of avidin-HRP solution into each hole, uniformly mixing, incubating for 17 min at 37 ℃, washing with washing liquor for 6 times, respectively adding 50 mu l of substrate A solution and 50 mu l of substrate B solution into each hole, uniformly mixing, detecting a luminous value within 1-5 min, and calculating a concentration value of the sample through a calibrator curve.

Example 3 evaluation of the Performance of the kit of the present invention

1. Sensitivity detection

Blank Limit (LOB): 5 blank clinical samples with a value close to 0 are repeated for 3 times for 4 days in total, and 60 data with non-negative results are obtained;

detection Line (LOD): after LOB is determined, collecting 5 low-value clinical samples of which the LOB is 1-4 times of that of the sample, repeating each sample for 3 times, and performing 4 days in total to obtain 60 data;

functional Sensitivity (FS): by adopting data in an LOD experiment, 5 concentration samples are measured 3 times per day for 4 days in total, 12 results are obtained for each sample, the mean value, SD and CV percent of each sample are calculated, and the concentration closest to 20 percent is the functional sensitivity; specific data are shown in table 1.

TABLE 1 detection of sensitivity of the kit of the invention

Table 1 the results show that: the concentration which can be accurately detected by the first batch is 10.701ng/mL, and the concentration which can be accurately detected by the second batch is 11.331 ng/mL, which meet the requirements.

2. Detection of precision

Two batches of reagents are respectively taken for precision tests, the quality control substances and clinical high/medium/low value samples are respectively used for repeated measurement for 20 times, the variation of the measured concentration is calculated, and the measurement results are shown in tables 2 and 3.

TABLE 2 detection of the precision of the kit of the invention

TABLE 3 detection of the precision of the kit of the invention

The results show that the coefficient of variation is less than 8%.

3. Kit cross reaction assessment

The kits of the present invention were examined for interference of norepinephrine, epinephrine, dopamine, methoxynorepinephrine, and levodopa, with the results shown in table 4 below.

TABLE 4

The results show that: the cross rate of the main cross substances and the main cross substances is less than 0.05 percent, and the kit has no interference.

4. Clinical Performance assessment of the kit of the invention

The kit and HPLC are used for simultaneously measuring 40 urine samples for clinical diagnosis of adrenal cortex hyperplasia, hypertension, pheochromocytoma, primary hyperparathyroidism and the like, and the correlation with HPLC is shown in figure 1: y =0.9553x +11.93, r²=0.9698, indicating that the kit can be used to aid in the timely diagnosis and treatment of pheochromocytoma.

Claims

1. A methoxy adrenaline luminescence immunoassay kit is characterized in that: comprises a detection system and a sample pretreatment system; wherein:

the detection system comprises a solid phase carrier material, a methoxyl adrenaline antibody solution, an avidin-linked tracer solution and a calibrator; the preparation method of the solid phase carrier material comprises the following steps:

washing selected magnetic microsphere stock solution for 2-5 times by PBS (phosphate buffer solution) with the volume being 10 times that of the stock solution, activating by EDC, NHS or glutaraldehyde, coating the activated magnetic microspheres and antibodies with the concentration being 5-40 mug/mL through chemical connection, cleaning the coated magnetic microspheres, sealing by using a sealing solution, fixing the volume and subpackaging to obtain magnetic particle suspension liquid with magnetic particles connected with a second antibody, magnetic particles connected with a FITC (FITC) antibody or magnetic particles connected with an anti-methoxyadrenaline antibody; wherein the diameter of the magnetic microsphere is 0.1-8 μm, and the surface of the magnetic microsphere is connected with one or more active functional groups including but not limited to-COOH and-NH₂OH, which has the property that the magnet can be quickly magnetized under the action of an external magnetic field, and the remanence is zero after the magnetic field is removed;

the preparation method of the avidin connection tracer solution comprises the following steps: preparing a diluent according to a formula of 0.05-0.2M Tris-NaCL, 0.5-4% BSA, 0.5-2% aminopyrine, 0.5-2% iodopropyne n-butyl carbamate and 0.1-2% PEG-4000, adding avidin according to a ratio of 1: 5000-1: 50000 to obtain an avidin-HRP solution, an avidin-ALP solution, an avidin-luminol solution, an avidin-isoluminol solution, an avidin-adamantane solution or an avidin-acridine ester solution, uniformly mixing, and storing at 2-8 ℃ for later use;

the preparation method of the methoxy adrenaline antibody solution comprises the following steps: preparing an antibody solution diluent according to a formula of 0.05-0.2M Tris-NaCL, 0.5-4% BSA, 0.5-2% ADP, 0.5-2% iodopropyne n-butyl carbamate and 0.1-2% PEG-4000, adding a methoxy adrenalin antibody according to 0.5-10 mu g/mL to prepare an antibody solution, uniformly mixing, and storing at 2-8 ℃ for later use;

the calibrator is a series of calibrators with a plurality of different concentration points, wherein the concentration of the methoxy adrenergic antigen ranges from low to high from 0ng/mL to 2000ng/mL, and a buffer solution of the calibrator contains 1-50 g/L of bovine serum albumin and a preservative;

the sample pretreatment system comprises an acidification liquid, an acylating agent and an alkaline buffer liquid;

the detection method of the methoxy adrenergic luminescence immunoassay kit comprises the following steps:

the sample pretreatment process comprises the following steps: putting 10-50 mu L of urine detection sample into a 6 mL glass bottle, adding 100-300 mu L of acidification solution, carrying out water bath acidification for 0.5-2 h, cooling to room temperature, adding 20-100 mu L of acylating agent, oscillating on an oscillator for 15-30 min, and transferring to a reaction cup;

and (3) detection: the methoxy adrenaline antibody exists in the form of antibody solution, the magnetic particle is connected with a second antibody capable of reacting with the methoxy adrenaline antibody, and the specific sample adding steps are as follows: a. respectively adding 10-100 mu L of the treated calibrator and the sample into different reaction holes; b. adding 10-50 mu L of magnetic particle suspension and 10-100 mu L of antibody solution; c. incubating at 37 ℃ for 15-30 min, and cleaning for 5 times in a magnetic environment; d. adding 50-200 mu L of avidin solution marked with a tracer; e. incubating at 37 ℃ for 15-30 min, and cleaning for 5 times in a magnetic environment; f. adding a luminescent substrate, and detecting the intensity of the optical signal.

2. The methoxyepinephrine luminescence immunoassay kit of claim 1, wherein: the calibrator is a series of calibrators with a plurality of different concentration points, wherein the concentration of the methoxy adrenergic antigen ranges from low to high from 0ng/mL to 2000ng/mL, and the buffer solution of the calibrator contains 1-50 g/L of bovine serum albumin and a preservative.

3. The methoxyepinephrine luminescence immunoassay kit of claim 1, wherein: the acylating agent in the sample pretreatment system is one-end biotinylated acylating agent, and comprises 6- (maleimide) caproic acid succinimidyl ester, N- [6- (biotin amino) caproyl ] -6-aminocaproic acid, N-succinimidyl ester or N-succinimidyl 6-biotin aminocaproic acid.

4. The methoxyepinephrine luminescence immunoassay kit of claim 1, wherein: the pH value of the acidizing fluid in the sample pretreatment system is less than 3; the pH of the alkaline buffer is > 8.